Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: A nested case-control study based on Italian healthcare utilization databases

Cristina Bosetti, Matteo Franchi, Federica Nicotra, Rosario Asciutto, Luca Merlino, Carlo La Vecchia, Giovanni Corrao

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Insulin and other antidiabetic drugs may modulate hepatocellular carcinoma (HCC) risk in diabetics. Methods: We have analyzed the role of various antidiabetic drugs on HCC in a nested case-control study using the healthcare utilization databases of the Lombardy Region in Italy. This included 190 diabetic subjects with a hospital discharge reporting a diagnosis of malignant HCC and 3772 diabetic control subjects matched to each case on sex, age, date at cohort entry, and duration of follow-up. Results: Increased risks of HCC were found for use of insulin (odds ratio [OR]=3.73, 95% confidence interval [CI] 2.52-5.51), sulfonylureas (OR=1.39, 95%CI 0.98-1.99), and repaglinide (OR=2.12, 95%CI 1.38-3.26), while a reduced risk was found for use of metformin (OR=0.57, 95%CI 0.41-0.79). The risk of HCC increased with increasing duration of insulin use (OR=2.52 for

Original languageEnglish
Pages (from-to)771-778
Number of pages8
JournalPharmacoepidemiology and Drug Safety
Volume24
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

Keywords

  • Antidiabetics
  • Diabetes
  • Hepatocellular carcinoma
  • Insulin
  • Metformin
  • Pharmacoepidemiology

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology

Fingerprint Dive into the research topics of 'Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: A nested case-control study based on Italian healthcare utilization databases'. Together they form a unique fingerprint.

Cite this